📊 MBOT Key Takeaways
Is Microbot Medical Inc. (MBOT) a Good Investment?
Microbot Medical is a pre-revenue stage medical device company with minimal commercialization ($2K revenue), burning $13M annually with only 3.9M in cash reserves providing less than 4 months of runway. Despite strong balance sheet composition and zero debt burden, the company faces existential risk from unsustainable cash burn and inability to generate meaningful revenue, indicating significant development or commercialization challenges.
Microbot Medical remains effectively pre-revenue, with only $2.00K of revenue against a $13.14M net loss and negative free cash flow of $13.11M, indicating that current operations are not commercially self-sustaining. While the balance sheet shows low leverage and strong reported liquidity ratios, the absolute cash balance of $3.91M appears weak relative to annual cash burn, making funding risk a central fundamental concern. The core issue is not solvency today, but the lack of proven revenue scale, persistent operating losses, and poor growth quality.
Why Buy Microbot Medical Inc. Stock? MBOT Key Strengths
- Negligible debt with 0.03x debt-to-equity ratio and strong balance sheet structure
- Adequate current ratio of 23.33x indicating no immediate liquidity crisis
- Large asset base of 81.5M suggesting accumulated R&D investments in surgical robotics technology
- Very low leverage with debt/equity of 0.03x and modest total liabilities relative to equity
- Strong reported current and quick ratios, indicating limited near-term balance sheet pressure from liabilities
- Net loss and EPS improved year over year, showing some reduction in loss intensity
MBOT Stock Risks: Microbot Medical Inc. Investment Risks
- Severe cash burn of $13M annually with only $3.9M cash reserves - approximately 3.6 months runway
- Essentially pre-revenue stage with only $2K in reported revenue indicating failed commercialization of surgical robotics platform
- Negative operating cash flow of $13M and deteriorating net loss position despite marginal revenue growth
- Extended period of unprofitability with -16.9% ROE suggests capital is being destroyed, not deployed efficiently
- Business is essentially pre-revenue, so margins and profitability metrics are not economically meaningful yet
- Operating cash flow of -$13.05M versus only $3.91M in cash implies substantial financing risk if commercialization is delayed
- Large recurring operating losses suggest dependence on external capital rather than internally generated cash
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Revenue generation and path to commercialization of surgical robotics products
- Operating cash flow improvement and timeline to cash flow breakeven
- Cash runway relative to quarterly operating cash burn
- Sustainable revenue growth from product commercialization rather than one-off or immaterial sales
Microbot Medical Inc. (MBOT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 23.33x current ratio provides a solid financial cushion.
MBOT Profit Margin, ROE & Profitability Analysis
MBOT vs Healthcare Sector: How Microbot Medical Inc. Compares
How Microbot Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Microbot Medical Inc. Stock Overvalued? MBOT Valuation Analysis 2026
Based on fundamental analysis, Microbot Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Microbot Medical Inc. Balance Sheet: MBOT Debt, Cash & Liquidity
MBOT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Microbot Medical Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MBOT Revenue Growth, EPS Growth & YoY Performance
MBOT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2016 | $32.8K | -$4.2M | N/A |
| Q2 2016 | $29.3K | $2.5M | N/A |
| Q1 2016 | $21.0K | -$9.4M | N/A |
| Q3 2015 | $37.0K | -$2.6M | N/A |
| Q1 2015 | $21.0K | -$7.6M | N/A |
| Q3 2014 | $171.4K | -$2.8M | N/A |
| Q2 2014 | $218.7K | -$5.9M | N/A |
| Q1 2014 | $208.6K | -$6.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Microbot Medical Inc. Dividends, Buybacks & Capital Allocation
MBOT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Microbot Medical Inc. (CIK: 0000883975)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBOT
What is the AI rating for MBOT?
Microbot Medical Inc. (MBOT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBOT's key strengths?
Claude: Negligible debt with 0.03x debt-to-equity ratio and strong balance sheet structure. Adequate current ratio of 23.33x indicating no immediate liquidity crisis. ChatGPT: Very low leverage with debt/equity of 0.03x and modest total liabilities relative to equity. Strong reported current and quick ratios, indicating limited near-term balance sheet pressure from liabilities.
What are the risks of investing in MBOT?
Claude: Severe cash burn of $13M annually with only $3.9M cash reserves - approximately 3.6 months runway. Essentially pre-revenue stage with only $2K in reported revenue indicating failed commercialization of surgical robotics platform. ChatGPT: Business is essentially pre-revenue, so margins and profitability metrics are not economically meaningful yet. Operating cash flow of -$13.05M versus only $3.91M in cash implies substantial financing risk if commercialization is delayed.
What is MBOT's revenue and growth?
Microbot Medical Inc. reported revenue of $2.0K.
Does MBOT pay dividends?
Microbot Medical Inc. does not currently pay dividends.
Where can I find MBOT SEC filings?
Official SEC filings for Microbot Medical Inc. (CIK: 0000883975) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBOT's EPS?
Microbot Medical Inc. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBOT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Microbot Medical Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBOT stock overvalued or undervalued?
Valuation metrics for MBOT: ROE of -16.9% (sector avg: 15%), net margin of -657,100.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBOT stock in 2026?
Our dual AI analysis gives Microbot Medical Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBOT's free cash flow?
Microbot Medical Inc.'s operating cash flow is $-13.0M, with capital expenditures of $60.0K. FCF margin is -655,300.0%.
How does MBOT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -657,100.0% (avg: 12%), ROE -16.9% (avg: 15%), current ratio 23.33 (avg: 2).